Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
|Articles|December 1, 2017
- Pharmaceutical Executive-12-01-2017
- Volume 37
- Issue 12
Pharmaceutical Executive, December 2017 Issue (PDF)
Click the title above to open the Pharmaceutical Executive December 2017 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 9 years ago
Global Health: Fighting the Good Fightalmost 9 years ago
Global Health: Partnerships Hold the Keyalmost 9 years ago
First Foray into Digital Adherencealmost 9 years ago
Global Health: Messages of Hopealmost 9 years ago
A Year of Transformation for Science & Medicinealmost 9 years ago
Access and Reimbursement for Adoptive T-Cell Transfer Drugsalmost 9 years ago
Will Europe Turn a Corner in Personalized Medicine?almost 9 years ago
Fulfilling the Vision of Science: AstraZeneca's Ruud Dobberalmost 9 years ago
Country Report: CanadaAdvertisement
Related to this article
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Teva acquires BioXcel’s BXCL501, under FDA review for at-home agitation use; Rumi Therapeutics gains an option on Enthorin’s Fragile X PDE2 inhibitor.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.
Advertisement
Advertisement
Trending on PharmExec
1
The Next Biopharma Revolution: Quantum Computing
2
How Medications like XOCOVA Prevent Illness After Exposure to COVID-19
3
Roundup: Astellas Licenses IL-12 Fusion Protein From Audax in Deal Worth Up to $1.34 Billion, EVERSANA Acquires Health Economics Firm Estima Scientific
4
Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin
5